Interpharma, Quintiles and Temasek to Form Pharma Commercialization Joint Venture in Asia Pacific With US$112 Million Investment Fund

Hong Kong and Singapore and Research Triangle Park, North Carolina(ots/PRNewswire) - Three global companies have announced a jointventure to commercialize pharmaceutical products in the Asia Pacificregion. Partners in the joint venture, which will have an investmentfund totaling US$112 million, include leading Asia Pacificpharmaceutical services group, Interpharma Asia Pacific, parent ofdrug distributor Zuellig Pharma; Asia investment company TemasekHoldings (Private) Limited; and Quintiles Transnational Corp., theworld's leading pharmaceutical services organization, who has signeda letter of intent to join the venture. Each partner is expected tomake an equal investment in the joint venture and own one-third eachof the company.

The joint venture will draw on each partner's wide marketknowledge, experience and success in both the Asia Pacific and globalhealthcare markets to acquire existing and new pharmaceuticalproducts from research-based drug companies targeted at the needs ofthe Asia Pacific region. This service helps drug companies focustheir resources on R&D and provides outsourcing for productregistration and sales and marketing of their mature brandportfolios.

PharmaLink, the specialist Asia Pacific pharmaceutical marketingservices division of Interpharma, will be transferred to the new JVand will help negotiate the acquisition of these products and theirsubsequent marketing in the Asia Pacific healthcare market. ZuelligPharma will provide distribution and logistics expertise. Quintileswill contribute regional commercialization expertise and experiencein pharmaceutical outsourcing partnerships.

Mr Fritz Horlacher, Chief Executive of Interpharma said,"Interpharma has been in Asia Pacific for more than 60 years andoperates in 13 countries in the region. We believe that we will beable to actively apply our experience and knowledge of local Asianmarkets. We are pleased to partner with Temasek and Quintiles in thisventure as we all share a common vision of the exciting growthopportunities in the Asia Pacific healthcare environment."

Dr Dennis Gillings, CBE, Chairman and Chief Executive Officer ofQuintiles Transnational said, "The joint venture can provide flexiblesolutions for pharmaceutical customers in the Asia Pacific region inmanaging their product portfolios. Quintiles' global clinicalknowledge aids in portfolio evaluation and our experience incommercialization and pharmaceutical partnerships complements wellthe capabilities of our JV partners. Together, we are acommercialization powerhouse."

Mr S Iswaran, Managing Director, Strategic Development of TemasekHoldings said, "Temasek has invested in several biotech and pharmaventures globally. This investment fits in well with our view ofgrowth prospects for Asia and our overall investment strategy for thelife sciences. We are pleased to partner with Interpharma andQuintiles, whose knowledge, networks and experience in Asia Pacificwill be valuable to the success of this joint venture."

According to a leading source of pharmaceutical marketintelligence, the Asia Pacific pharma market, currently estimated tobe US$21 billion, has more than doubled over the last 10 years and isprojected to double again over the next 10 years.

The joint venture will be managed by a professional team led by MrBrian Nichols, Chief Executive of PharmaLink, who has more than 30years' experience in the pharmaceutical industry in Asia Pacific.Formation of the three-way joint venture is subject to the executionof definitive agreements, which is expected to occur in a few months.

About Interpharma

Interpharma Asia Pacific is a pan-regional enterprise operatingvarious business units across Asia including Pharma Industries,Zuellig Pharma and PharmaLink. These business units provide servicesto the multi-national R&D-based pharmaceutical manufacturers. Pleasevisit www.zuelligpharma.com/ip

Pharma Industries is a leading provider of contract pharmaceuticalmanufacturing services in the Asia Pacific region. It providesproduct development, planning & procurement and commercialmanufacturing services. Please visit http://www.pharmaindustries.com

Zuellig Pharma, the distribution and logistics division ofInterpharma, is Asia Pacific's leading provider of cutting-edgelogistics services covering inventory management, warehousing,distribution and customer order management. Please visithttp://www.zuelligpharma.com

PharmaLink, the specialist marketing services division ofInterpharma Asia Pacific, offers the complete marketing solution inAsia Pacific. With expertise in orphan drug management, regulatoryaffairs and sales and marketing teams, PharmaLink is Asia's leadingsales and marketing organization, being the ideal healthcaremarketing partner, providing a complete range of marketing servicesand support solutions that are attracting more pharmaceuticalcompanies, seeking to increase their growth or expand operations intoAsia Pacific. PharmaLink has established a reputation for sales andmarketing excellence with over 1,600 sales representatives marketingproducts in over 19 therapeutic areas.

For more information, please visit: http://www.pharmaLink.com

About Quintiles Transnational

Quintiles Transnational Corp. helps improve healthcare worldwideby providing a broad range of professional services, information andpartnering solutions to the pharmaceutical, biotechnology andhealthcare industries. Headquartered near Research Triangle Park,N.C., USA, Quintiles has offices in 50 countries and is the world'sleading pharmaceutical services organization.

For more information, visit the company's website athttp://www.quintiles.com

Information in this press release contains "forward-lookingstatements." These statements involve risks and uncertainties thatcould cause actual results to differ materially, including, withoutlimitation, the risk that the parties might not reach final agreementas planned and the joint venture might not commence operations asplanned or at all. Additional factors that could cause actual resultsto differ materially are discussed in Quintiles' recent filings withthe Securities and Exchange Commission, including but not limited toits annual report on Form 10-K, its quarterly report on Form 10-Q andits current reports on Form 8-K.

About Temasek Holdings

Temasek Holdings is an Asia investment company headquartered inSingapore. It is committed to maximizing long-term shareholder valueas an active investor and shareholder of successful enterprises.

Established in 1974, it manages a diversified global portfolio ofUS$54 billion, spanning Singapore, Asia and the OECD economies. Itsinvestments are in a range of industries: telecommunications andmedia, financial services, property, transportation and logistics,energy and resources, infrastructure, engineering and technology, aswell as pharmaceuticals and biosciences.

Singapore-based Temasek-linked companies include well-known listedfirms such as Singapore Airlines, SingTel, DBS Bank, SMRT Corporationand Neptune Orient Lines. Its overseas investments include ICICIBank, Matrix Laboratories and the Apollo Hospital group in India,Bank Danamon and Bank Internasional Indonesia in Indonesia, QuintilesTransnational Corp in the US, as well as Telekom Malaysia.

For more information, please visit:http://www.temasekholdings.com.sg

Web site: http://www.quintiles.com http://www.zuelligpharma.com/ip http://www.pharmaindustries.com http://www.zuelligpharma.com http://www.pharmaLink.com

ots Originaltext: Quintiles Transnational Corp.Im Internet recherchierbar: http://www.presseportal.de

Contact:Mr Mike Hampton, Regional Manager Strategic Projects of Interpharma Asia Pacific, +852-2845-2677, or fax, +852-2877-5647, or mhampton@zuelligpharma.com ; or Pat Grebe, VP, Corporate Communication of Quintiles Transnational, +1-919-998-2000, or pat.grebe@quintiles.com ; or Ms Rachel Lin, Associate Director, Corporate Communications of Temasek Holdings, DID, +65-6828-6766, or Mobile, +65-96661855, or Fax, +65-6828-6266, or rachellin@temasek.com.sg ; or Mr Brian Nichols, Chief Executive of PharmaLink, +852-2588-8103, or fax, +852-2877-5647, or bnichols@pharmalink.com

Quintiles Transnational Corp.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Interpharma, Quintiles and Temasek to Form Pharma Commercialization Joint Venture in Asia Pacific With US$112 Million Investment Fund